Marie H. Deventer

Assessment of structure-activity relationships and biased agonism at the Mu opioid receptor of novel synthetic opioids using a novel, stable bio-assay platform

Lakshmi Vasudevan, Marthe M. Vandeputte, Marie H. Deventer et al. · Biochemical Pharmacology · 2020 · 53 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Cannabinoid receptor activation potential of the next generation, generic ban evading OXIZID synthetic cannabinoid receptor agonists

Marie H. Deventer, Katleen Van Uytfanghe, Inge M. J. Vinckier et al. · Drug Testing and Analysis · 2022 · 40 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

A new cannabinoid receptor 1 selective agonist evading the 2021 “China ban”: ADB‐FUBIATA

Marie H. Deventer, Katleen Van Uytfanghe, Inge M. J. Vinckier et al. · Drug Testing and Analysis · 2022 · 30 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

Structure–activity relationships of valine, <i>tert</i>-leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA

Eric Sparkes, Elizabeth A. Cairns, Richard C. Kevin et al. · RSC Medicinal Chemistry · 2021 · 29 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Dual-Acting Small Molecules: Subtype-Selective Cannabinoid Receptor 2 Agonist/Butyrylcholinesterase Inhibitor Hybrids Show Neuroprotection in an Alzheimer’s Disease Mouse Model

Philipp Spatz, Sophie A. M. Steinmüller, Anna Tutov et al. · Journal of Medicinal Chemistry · 2023 · 27 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17